AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Contact information
Fred Kim
734-516-8732
fredkim@aribiousa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOURISE Awards 2025: Tokyo, New York, Ancash and Paris Take Top Honors at Inaugural TOURISE Awards12.11.2025 20:31:00 EET | Press release
The very first winners of the TOURISE Awards have been announced, recognizing the destinations redefining exploration, hospitality, and cultural connection for the modern traveler, setting new benchmarks for innovation and excellence to deliver truly unforgettable visitor experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112648089/en/ His Excellency Ahmed Al-Khateeb, Minister of Tourism and TOURISE Chairman, celebrates with the winners of the TOURISE Awards Taking place as part of the inaugural TOURISE Summit, held under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, Tokyo, Japan, emerged as the big winner, clinching the coveted title of Best Overall Destination. In addition, Tokyo was also recognized as both the Best Food & Culinary and Best Entertainment destination, affirming its status as a global capital of innovation, energy, and unfor
Telcoin Makes U.S. Banking History with Approval to Launch the First Regulated Digital Asset Bank12.11.2025 20:00:00 EET | Press release
Telcoin today announced its final charter approval from the Nebraska Department of Banking and Finance to launch Telcoin Digital Asset Bank, the first Digital Asset Depository Institution in the United States. The charter positions Telcoin to become the first true blockchain bank, directly connecting U.S. bank accounts to regulated “Digital Cash” stablecoins. Its flagship product, eUSD, will be the first bank-issued, on-chain U.S. dollar stablecoin, offering consumers and businesses a secure, compliant way to use Digital Cash for payments, remittances, and savings. Notably, it is also the first bank charter to explicitly authorize connecting U.S. consumers to DeFi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112119122/en/ Telcoin’s eUSD and other global Digital Cash stablecoins represent an evolution of money that is programmable and interoperable, designed to move seamlessly across blockchain and traditional financial
Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn12.11.2025 20:00:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 toward its next clinical milestones. Globally recognized for her groundbreaking contributions to cancer immunology, Prof. Finn has led major discoveries in tumor antigens. She identified the MUC1 tumor antigen, a cornerstone in cancer research, and discovered cyclin B1 as a promising target for anti-cancer immunotherapy. Over her career, she has authored more than 220 peer-reviewed publications and co-led extensive clinical trials across pancreatic, colon, breast, prostate, and lung cancers. She also served as President of the American Associa
Mindbreeze Named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment12.11.2025 19:01:00 EET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, has been named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment (doc #US53011225, November 2025). In the IDC MarketScape 14 vendors of knowledge discovery software were evaluated. For the assessment, IDC divided potential key measures for success into two primary categories: capabilities and strategies. Get your complimentary copy of the excerpt here. The IDC MarketScape notes, “Companies looking for reliable, context-aware insights from internal and external sources should consider Mindbreeze. The platform enables decision making for compliance, risk management, and strategic planning, appealing to business areas such as customer service, finance, legal, and HR. It can tailor pre-built search applications to specific departments for search while supporting broader knowledge management and digital workspace initiatives.” "We are proud to be rec
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 18:12:00 EET | Press release
Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors, EIB’s development arm EIB Global commits €50m, while Proparco will commit €20m and British International Investment has received approval for a €10m commitment, subject to final negotiations. Averrhoa NBS is a SFDR1 Article 9 impact fund overseen by Ardian’s Infrastructure team in partnership with aDryada, a specialist developer and manager of large-scale ecosystem restoration projects. The strategy is dedicated to investing in projects to reforest and restore wetlands and mangroves, intended to protect biodiversity while enab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom